Format

Send to

Choose Destination
See comment in PubMed Commons below
Menopause. 2013 Feb;20(2):162-8. doi: 10.1097/gme.0b013e31826560da.

Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer.

Author information

  • 1Department of Obstetrics and Gynecology, Örebro University Hospital, Örebro, Sweden. juliane.baumgart@orebroll.se

Abstract

OBJECTIVE:

The goal of this study was to investigate sexual function in postmenopausal breast cancer patients treated with aromatase inhibitors.

METHODS:

A population-based, cross-sectional study was conducted among postmenopausal breast cancer patients on adjuvant endocrine treatment and age-matched controls with and without estrogen treatment. Sexual function was assessed with a standardized questionnaire.

RESULTS:

In all, 42.4% of aromatase inhibitor-treated breast cancer patients were dissatisfied with their sex life in general, and 50.0% reported low sexual interest; this was significantly more common than in tamoxifen-treated patients and controls (P < 0.05). Aromatase inhibitor-treated patients reported insufficient lubrication in 73.9% and dyspareunia in 56.5% of cases, which were significantly more common than in controls, irrespective of hormonal use (P < 0.05). Tamoxifen-treated patients reported significantly more dyspareunia (31.3%; P < 0.05) but resembled controls in all other concerns.

CONCLUSIONS:

Our findings suggest that sexual dysfunction in aromatase inhibitor-treated women is a greatly underestimated problem.

PMID:
22990756
DOI:
10.1097/gme.0b013e31826560da
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center